Lv0
0 积分 2025-02-27 加入
Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer
7小时前
求助中
Targeted protein degradation for cancer therapy
10小时前
已完结
TGF-β receptors: In and beyond TGF-β signaling
11天前
已完结
Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
12天前
已完结
Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy
2个月前
已关闭
Broadly therapeutic antibody provides cross-serotype protection against enteroviruses via Fc effector functions and by mimicking SCARB2
2个月前
已完结
Germinal center reaction and output: recent advances
3个月前
已完结
Germinal Centers
3个月前
已完结
Recent Developments Toward Antibody Engineering and Affinity Maturation
3个月前
已完结
Chinese innovative drug R&D trends in 2024
3个月前
已完结
皖公网安备34019202002308
